The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2019

Filed:

Dec. 19, 2014
Applicants:

Novartis Ag, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Jennifer Brogdon, Cambridge, MA (US);

Boris Engels, Arlington, MA (US);

David Jonathan Glass, Cambridge, MA (US);

Brian Granda, Cambridge, MA (US);

John Hastewell, Cambridge, MA (US);

Andreas Loew, Cambridge, MA (US);

Joan Mannick, Cambridge, MA (US);

Michael Milone, Cherry Hill, NJ (US);

Leon Murphy, Cambridge, MA (US);

William Raj Sellers, Cambridge, MA (US);

Huijuan Song, Shanghai, CN;

Brian Edward Vash, Cambridge, MA (US);

Jan Weiler, Cambridge, MA (US);

Qilong Wu, Shanghai, CN;

Li Zhou, Cambridge, MA (US);

Assignees:

Novartis AG, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 31/436 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/725 (2006.01); C12N 9/90 (2006.01); C07K 14/74 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 31/436 (2013.01); A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70539 (2013.01); C07K 14/70578 (2013.01); C07K 14/71 (2013.01); C12N 9/90 (2013.01); C12Y 502/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/70 (2013.01);
Abstract

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.


Find Patent Forward Citations

Loading…